There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Matinas BioPharma (MTNB – Research Report) and Talaris Therapeutics (TALS – Research Report) with bullish sentiments. Matinas BioPharma (MTNB) In a report released today, Andrew Fein from H.C. Wainwright reiterated a Buy rating on Matinas BioPharma, with a price target of $3.00. The company's shares closed last Monday at $0.88. According to TipRanks.
https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-matinas-biopharma-mtnb-and-talaris-therapeutics-tals?utm_source=advfn.com&utm_medium=referral